Clinical trial
GALLANT 6 Tesaglitazar vs. Pioglitazone
NCT00214565 · AstraZeneca, Industry · Terminated
Key facts
| NCT number | NCT00214565 |
|---|---|
| Title | GALLANT 6 Tesaglitazar vs. Pioglitazone |
| Official title | A 24-Wk Randomised, Double-Blind, Multi-Centre, Active-Controlled (Pioglitazone) Study to Evaluate the Efficacy, Safety & Tolerability of Tesaglitazar Therapy When Administered to Patients With Type 2 Diabetes |
| Lead sponsor | AstraZeneca, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | Galida |
| Enrollment | 1,450 |
| Start date | Aug 1, 2004 |
| Primary completion | Oct 1, 2006 |
| Completion | Oct 1, 2006 |
| First posted | Sep 22, 2005 |
| Last update posted | Nov 19, 2010 |
| Countries | Argentina, Brazil, Canada, Finland, Mexico, Norway, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: